Amarin | AMRN - Interest Expense On Debt


Amarin reported $3K in Interest Expense on Debt for its fiscal quarter ending in December of 2024.





Interest Expense On Debt Change Date
AbbVie USD 740M 40M Jun/2025
Alnylam Pharmaceuticals USD 129.34M 84.94M Dec/2025
Amarin USD 3K 5K Dec/2024
AstraZeneca USD 484M 181M Dec/2025
BioCryst Pharmaceuticals USD 14.14M 5.53M Dec/2025
DBV Technologies USD 461K 323.71K Mar/2025
Esperion Therapeutics USD 22.64M 585K Dec/2025
GlaxoSmithKline GBP 188M 21M Dec/2025
Halozyme Therapeutics USD 4.91M 615K Dec/2025
Heron Therapeutics USD 600K 100K Dec/2024
Ionis Pharmaceuticals USD 18M 0 Dec/2025
Nektar Therapeutics USD 9.77M 3.75M Dec/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 304M 23M Dec/2025